Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Mark Sostek"'
Autor:
Brian Feagan, David Rubin, Stephen Hanauer, William Sandborn, Walter Reinisch, David Lichter, Barbara McGovern, Judith Bebchuk, Guangyong Zou, Sherry Wang-Weigand, Mark Sostek, Lisa von Moltke
Publikováno v:
Gastroenterology. 164:S23-S24
BACKGROUND Endoscopic assessment of disease severity is a key component of ulcerative colitis (UC) clinical studies. However, interobserver variability may contribute to bias in selecting study candidates and evaluating response rates. Scoring by bli
Autor:
Brian Feagan, David Rubin, Stephen Hanauer, William Sandborn, Shiraz Farooq, Henry Levine, Caterina Oneto, David Lichter, Gabrielle Glick, Kelly Brady, Barbara McGovern, Sherry Wang-Weigand, Mark Sostek, Lisa Grier, David Kerman, Bharat Misra, Kenolisa Onwueme, Jeffrey Axler, Lisa von Moltke
Publikováno v:
American Journal of Gastroenterology. 117:S8-S8
Publikováno v:
Pain Practice. 18:505-514
OBJECTIVE To summarize results from pain and opioid use assessments with naloxegol in adults with opioid-induced constipation (OIC) and chronic noncancer pain. METHODS Two phase 3 randomized, double-blind, 12-week studies evaluated the efficacy and s
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
Opioid-induced constipation (OIC) is a common side effect of opioid pharmacotherapy for the management of pain because opioid agonists bind to µ-opioid receptors in the enteric nervous system (ENS). Naloxegol, a polyethylene glycol derivative of nal
Publikováno v:
Clinical Therapeutics. 39:75-88
Purpose Opioid-induced constipation (OIC) is a bothersome side effect of opioid use for the management of noncancer pain, affecting patients’ health-related quality of life and chronic-pain management. The objective of this study was to examine the
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Naloxegol is a polyethylene glycol derivative of naloxone approved in the US as a once-daily oral treatment for opioid-induced constipation (OIC) in adults with chronic noncancer pain. Population exposure-response models were constructed based on dat
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Naloxegol, a peripherally acting μ-opioid receptor antagonist for the treatment of opioid-induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P-glycoprotein (P-gp) transporter. By integrating in silico, preclinical, and cl
Publikováno v:
British Journal of Clinical Pharmacology. 81:89-100
Aims Naloxegol, a polyethylene glycol conjugated derivative of the opioid antagonist naloxone, is in clinical development for treatment of opioid-induced constipation (OIC). The aim of the study was to develop a population pharmacokinetic model descr
Publikováno v:
Journal of cardiovascular pharmacology and therapeutics. 23(4)
Background: Naloxegol is a novel selective, peripherally acting μ-opioid receptor antagonist for treating opioid-induced constipation (OIC) in patients with chronic pain syndromes. We analyzed the cardiovascular (CV) safety of naloxegol based on dat
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. Materials and methods [14C]-Labeled naloxegol (27 mg, 3.43 MBq) was